3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
439
Stomach Neoplasms
248
Carcinoma, Hepatocellular
246
Rectal Neoplasms
211
Colonic Neoplasms
204
Pancreatic Neoplasms
172
Esophageal Neoplasms
113
Neoplasm Metastasis
75
Liver Neoplasms
71
Neoplasms
63
Esophageal Squamous Cell Carcinoma
63
Gastrointestinal Stromal Tumors
36
Cholangiocarcinoma
36
Gastrointestinal Neoplasms
31
Parkinson Disease 4, Autosomal Dominant Lewy Body
25
Gallbladder Neoplasms
25
Adenocarcinoma Of Esophagus
24
Biliary Tract Neoplasms
23
Anus Neoplasms
22
Adenocarcinoma
21
Recurrence
19
Bile Duct Neoplasms
19
Breast Neoplasms
18
Digestive System Neoplasms
17
Lung Neoplasms
13
Prostatic Neoplasms
12
Uterine Cervical Neoplasms
11
Carcinoma
11
Digestive System Diseases
10
Peritoneal Neoplasms
9
Interventions
Ramucirumab
1
Fluorouracil
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Metastatic Gastric Adenocarcinoma
×
Gastrointestinal
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts